This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Myriad wins UPC ruling as GXD-Bio breast cancer patent is revoked

By Inbar Preiss ( December 22, 2025, 15:01 GMT | Insight) -- The Unified Patent Court revoked GXD-Bio’s breast cancer testing patent, rejecting infringement claims against Myriad’s EndoPredict breat cancer test and clearing the way for continued European marketing after finding added subject matter.South Korean biotech company GXD-Bio lost a Unified Patent Court infringement action against American genetic testing firm Myriad Genetics and its European affiliates after the court revoked the breast cancer testing patent and dismissed the infringement claims....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login